SCHEMBL3626600

SCHEMBL3626600

CCCCCCCCCCCCCCCC(=O)n1ccc(N)nc1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SQOR Q9Y6N5 3/20 0.43
▸ OXER1 Q8TDS5 3/20 0.43
▸ EP300 Q09472 3/20 0.43
▸ ELANE P08246 1/20 0.40
▸ NAAA Q02083 2/20 0.38
▸ FAAH O00519 1/20 0.38
▸ FGFR1 P11362 3/20 0.38
▸ GABRP O00591 1/20 0.38
▸ GABRD O14764 1/20 0.38
▸ GABRA1 P14867 1/20 0.38
▸ GABRB1 P18505 1/20 0.38
▸ GABRG2 P18507 1/20 0.38
▸ GABRB3 P28472 1/20 0.38
▸ GABRA5 P31644 1/20 0.38
▸ GABRA3 P34903 1/20 0.38
▸ GABRA2 P47869 1/20 0.38
▸ GABRB2 P47870 1/20 0.38
▸ GABRA4 P48169 1/20 0.38
▸ GABRE P78334 1/20 0.38
▸ GABRA6 Q16445 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11016973 1.00 SQOR (0.43) SQOROXER1EP300ELANENAAA
SCHEMBL11018469 1.00 SQOR (0.43) SQOROXER1EP300ELANENAAA
SCHEMBL11015092 0.99 EP300 (0.41) SQOROXER1EP300ELANENAAA
SCHEMBL1334906 0.82 CYP11B1 (0.38) EP300ELANEFGFR1GABRPGABRD
SCHEMBL17371974 0.79 PDE3A (0.36) EP300FGFR1
SCHEMBL8450945 0.78 PSMB11 (0.39) FAAH
SCHEMBL11015799 0.74 CA2 (0.41) FGFR1GABRPGABRDGABRA1GABRB1
SCHEMBL7165218 0.73 SQOR (0.45) SQOROXER1ELANENAAAFAAH
SCHEMBL13975422 0.73 FGFR1 (0.48) EP300FGFR1
SCHEMBL13092480 0.72 TLR8 (0.49) SQOROXER1ELANENAAAFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2148676-A1 USE OF SAPACITABINE TO TREAT PROLIFERATIVE DISEASE Cyclacel Limited (GB) 2010-02-03 — — EP disclosed
WO-2009136158-A1 PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHEIS OF 2'-CYANO-2'-DEOXY-N4-PALMITOYL-1-BETA-D-ARABINOFURANOSYLCYTOSINE CYCLACEL LIMITED (GB) 2009-11-12 — — WO disclosed
WO-2009136162-A1 INTERMEDIATE AND PROCESSES INVOLVED IN THE PREPARATION OF 2 ' -CYANO-2 ' -DE0XY-N4-PALMIT0YL-1-BETA-ARABIN0FURAN0SYLCYTOSINE CYCLACEL LIMITED (GB) 2009-11-12 — — WO disclosed
WO-2008132443-A1 USE OF SAPACITABINE TO TREAT PROLIFERATIVE DISEASE CYCLACEL LIMITED (GB) 2008-11-06 — — WO disclosed
EP-1962814-A2 CRYSTALLINE PYRIMIDINE NUCLEOSIDE DERIVATIVES SUSPENSIONS IN CAPSULES Cyclacel Limited (GB) 2008-09-03 — — EP disclosed
EP-1945265-A1 ANTIPROLIFERATIVE COMBINATION COMPRISING CYC-682 AND A CYTOTOXIC AGENT Cyclacel Limited (GB) 2008-07-23 — — EP disclosed
WO-2007132228-A1 COMBINATION OF CNDAC WITH A 2-SUBSTITUTED-4-HETER0ARYL-PYRIMIDINE AMINE AND USE THEREOF IN THE TREATMENT OF A PROLIFERATIVE DISORDER CYCLACEL LIMITED (GB) 2007-11-22 — — WO disclosed
WO-2007072061-A2 CRYSTALLINE PYRIMIDINE NUCLEOSIDE DERIVATIVES SUSPENSIONS IN CAPSULES CYCLACEL LIMITED (GB) 2007-06-28 — — WO disclosed
WO-2007054731-A1 ANTIPROLIFERATIVE COMBINATION COMPRISING CYC-682 AND A CYTOTOXIC AGENT CYCLACEL LIMITED (GB) 2007-05-18 — — WO disclosed
EP-0536936-B1 Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use SANKYO CO (JP) 1996-08-14 — — EP disclosed
EP-0136693-A2 Production of cytidine derivatives Takeda Chemical Industries, Ltd. (JP) 1985-04-10 — — EP disclosed
Send feedback